{"result": "(\"entity\"<|>ENDOCRINE SOCIETY<|>ORGANIZATION<|>The Endocrine Society is a professional organization that provides guidelines for the evaluation and treatment of hormone-related conditions, including adult growth hormone deficiency.)\n##\n(\"entity\"<|>GH<|>EVENT<|>Growth Hormone (GH) is a hormone that plays a key role in growth, body composition, and metabolism, and its deficiency can lead to various health issues.)\n##\n(\"entity\"<|>IGF-1<|>EVENT<|>Insulin-like Growth Factor 1 (IGF-1) is a hormone that is influenced by growth hormone levels and is used as a parameter to monitor treatment for growth hormone deficiency.)\n##\n(\"entity\"<|>GLUCAGON<|>EVENT<|>Glucagon is a hormone that raises blood glucose levels and is used in medical tests to stimulate growth hormone release.)\n##\n(\"entity\"<|>MORTALITY<|>EVENT<|>Mortality refers to the incidence of death in a population, and in this context, it is discussed in relation to the effects of growth hormone treatment.)\n##\n(\"entity\"<|>HYPOTHALAMIC-PITUITARY AXIS<|>EVENT<|>The hypothalamic-pituitary axis is a complex set of interactions between the hypothalamus and the pituitary gland that regulates various hormonal functions, including growth hormone secretion.)\n##\n(\"entity\"<|>PATIENT<|>PERSON<|>The patient in this context is an individual undergoing evaluation and treatment for growth hormone deficiency, experiencing various health challenges.)\n##\n(\"relationship\"<|>ENDOCRINE SOCIETY<|>GH<|>The Endocrine Society provides clinical practice guidelines for the evaluation and treatment of growth hormone deficiency, which includes the use of GH<|>8)\n##\n(\"relationship\"<|>GH<|>IGF-1<|>Growth hormone influences the levels of IGF-1, making it a critical parameter for monitoring treatment effectiveness<|>7)\n##\n(\"relationship\"<|>GH<|>GLUCAGON<|>Glucagon is used in tests to stimulate the release of growth hormone, indicating its role in diagnosing growth hormone deficiency<|>6)\n##\n(\"relationship\"<|>GH<|>MORTALITY<|>The treatment with growth hormone has implications for mortality rates, as it can improve certain health markers but does not necessarily reduce mortality<|>5)\n##\n(\"relationship\"<|>PATIENT<|>GH<|>The patient is undergoing treatment for growth hormone deficiency, which directly involves the administration of GH<|>9)\n##\n(\"relationship\"<|>PATIENT<|>IGF-1<|>The patient's treatment and monitoring involve measuring IGF-1 levels to assess the effectiveness of growth hormone therapy<|>8)\n##\n(\"relationship\"<|>PATIENT<|>GLUCAGON<|>The patient may undergo tests involving glucagon to evaluate their growth hormone response<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: estrés en el trabajo,                                                     A. Mejorar la capacidad vital y la recuperación después del ejercicio.\n        la situación clínica es la misma. ¿Cuál sería el siguiente paso que definiría mejor la\n        situación?                                                                                                                              B. Mejorar la osteoporosis.\n                                                                                                                                                C. Normalizar los niveles de IGF-1.\n        A. Medir IGF-1.                                                                                                                         D.  Reducir la mortalidad a largo plazo.\n        B. Medir IGF-1 e IGF-BP3.\n        C. Medir IGF-1 y GH tras hipoglucemia insulínica.                                                                                       COMENTARIO\n        D.  GH tras glucagón.\n                                                                                                                                                Desde que está disponible la GH recombinante, se                     ha  podido utilizar     en el déficit   de GH\n                                                                                                                                                del adulto de manera segura y eficaz. Las dosis de inicio del tratamiento en el adulto son\n        COMENTARIO                                                                                                                              menores que en el niño o en la transición y se suele comenzar con 0,2-0,4 mg/día, aunque\n        Como comentábamos en la anterior pregunta, lo más probable es que la falta de mejoría                                                   las mujeres en edad fértil o tratadas con estrógenos suelen precisar, de base, dosis algo\n        clínica de la paciente tras la correcta sustitución del déficit corticotropo se deba a la exis-                                         más altas que los hombres.\n        tencia de algún otro déficit hipofisario que habría que evaluar. Si recordamos las pruebas ya                                           El tratamiento con GH en el adulto produce un aumento de masa muscular, un descenso\n        realizadas, su función tiroidea y gonadal eran normales, pero el eje somatotropo no había                                               en la grasa corporal y mejoría en algunos parámetros de función cardíaca. Con todo esto,\n        sido evaluado.                                                                                                                          lo esperable sería encontrar también una mejoría en la función muscular, y de hecho un\n        La correcta valoración de la reserva funcional somatotropa no se puede limitar a pruebas                                                metaanálisis de ensayos aleatorizados controlados con placebo encontró mejoría de la ca-\n        basales; por tanto, las opciones A y B serían falsas. Precisamos realizar un test de estímulo.                                          pacidad de ejercicio. No obstante, en otro metaanálisis no se encontró mejoría en la fuerza\n        Existen varias opciones dentro de las pruebas funcionales para diagnosticar un déficit de                                               muscular en los pacientes tratados (aunque los datos sean conflictivos, veremos que, por\n        GH. En sus últimas guías, la Endocrine Society recomienda la hipoglucemia insulínica y el                                               descarte del resto de opciones, nos quedaríamos con la respuesta A como verdadera).\n        test de GHRH-arginina para establecer el diagnóstico de GH. Sin embargo, en algunos paí-                                                La evidencia respecto a la densidad mineral ósea es todavía más débil, y los estudios en\n        ses la GHRH no está disponible y la hipoglucemia insulínica tiene algunas contraindicacio-                                              los que se ha comparado el efecto del tratamiento con GH frente a placebo han encontrado\n        nes (ancianos, antecedentes de enfermedad cardiovascular o cerebrovascular y epilepsia).                                                mejoría mineral ósea en varones, pero no en mujeres (por tanto, descartaríamos la respues-\n        De hecho, algunos autores prefieren evitar la hipoglucemia insulínica por su necesidad de                                               ta B).\n        vigilancia médica, porque es incómodo para el paciente y no está exenta de riesgos. En                                                  Respecto a la mortalidad, el tratamiento con GH mejora algunos marcadores de riesgo car-\n        esos casos, lo que recomiendan es la estimulación con glucagón.                                                                         diovascular y se puede decir que no aumenta la mortalidad respecto a la población general\n        En este supuesto clínico, tanto la respuesta C como la D se refieren a pruebas de estímulo                                              pero tampoco ha demostrado reducción (respuesta D falsa).\n        que podrían diagnosticar correctamente un déficit de GH. Pero dado que nuestra paciente                                                 La normalización de la          GH sería    una   de   las formas     de  monitorizar el tratamiento          (junto\n        ha tenido crisis de ausencia y aún requiere tratamiento, sería recomendable elegir la opción                                            con la clínica del paciente, la valoración en los test de calidad de vida, el perfil lipídico o la\n        más segura, el test de GH tras glucagón (respuesta D).                                                                                  densidad mineral ósea). Se recomienda mantener la IGF-1 en la mitad superior del rango\n        Referencias:                                                                                                                            de normalidad, pero solo es un parámetro de control del tratamiento, no un objetivo del\n        • Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance L. Evaluation and treatment of adult growth hormone deficiency: An           tratamiento (respuesta C falsa).\n          Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587-609.\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}